MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- DR. REDDY'S LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Dr. Reddys Quarterly Results (REDY)
Here are the latest quarterly results of Dr. Reddys. For more details, see the Dr. Reddys financial fact sheet and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.
Dr. Reddys Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 38,341 | 35,539 | 37,365 | 38,175 | 38,646 | 40,296 | 38,582 | 48,128 | |
| Other income | Rs m | 430 | 449 | 504 | 1,282 | 1,023 | 833 | 4,301 | 540 | |
| Turnover | Rs m | 38,771 | 35,988 | 37,869 | 39,457 | 39,669 | 41,129 | 42,883 | 48,668 | |
| Expenses | Rs m | 30,414 | 29,903 | 29,677 | 30,582 | 30,600 | 32,107 | 31,165 | 37,490 | |
| Gross profit | Rs m | 7,927 | 5,705 | 7,771 | 7,593 | 8,046 | 8,189 | 7,417 | 10,638 | |
| Depreciation | Rs m | 2,715 | 2,763 | 2,787 | 2,786 | 2,903 | 2,872 | 2,890 | 3,131 | |
| Interest | Rs m | 172 | 178 | 195 | 208 | 241 | 245 | 298 | 303 | |
| Profit before tax | Rs m | 5,470 | 3,213 | 5,293 | 5,881 | 5,925 | 5,905 | 8,530 | 7,744 | |
| Tax | Rs m | 2,528 | 492 | 532 | 807 | 1,011 | 1,508 | 1,928 | -3,207 | |
| Profit after tax | Rs m | 2,942 | 2,721 | 4,761 | 5,074 | 4,914 | 4,397 | 6,602 | 10,951 | |
| Gross profit margin | % | 20.7 | 16.1 | 20.8 | 19.9 | 20.8 | 20.3 | 19.2 | 22.1 | |
| Effective tax rate | % | 46.2 | 15.3 | 10.1 | 13.7 | 17.1 | 25.5 | 22.6 | -41.4 | |
| Net profit margin | % | 7.7 | 7.7 | 12.7 | 13.3 | 12.7 | 10.9 | 17.1 | 22.8 | |
| Diluted EPS | Rs | 17.8 | 16.4 | 28.7 | 30.6 | 29.7 | 26.5 | 39.8 | 66.1 | |
| Diluted EPS (TTM) | Rs | 60.6 | 56.6 | 81.3 | 93.5 | 105.4 | 115.5 | 126.6 | 162.1 | |
 Subscriber Feature |
View | |||||||||
Interim results exclude extraordinary / exceptional items
Read: Dr. Reddys 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: ALEMBIC LTD VENUS REMEDIES PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA UNICHEM LAB
Compare DR. REDDYS LAB With: ALEMBIC LTD VENUS REMEDIES PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA UNICHEM LAB
Compare DR. REDDYS LAB With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)
Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.
Views on news
DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)
Jul 27, 2018 | Updated on Jul 27, 2018For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Use My Secret to Increase Your Trading Profits Today
Dec 10, 2019What to do after every trade.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020 (Profit Hunter)
Dec 5, 2019This corner of the market could provide more returns than blue chips in 2020.
Make the Most of the Smallcap Rebound with These Stocks (Profit Hunter)
Dec 3, 2019Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
What Is the IPO Euphoria Signaling Us About the Markets? (The 5 Minute Wrapup)
Dec 2, 20192019 will be remembered as the year of great money-making IPOs...
More|
| |
DR. REDDYS LAB SHARE PRICE
Dec 13, 2019 (Close)
TRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB 5-YR ANALYSIS
COMPARE DR. REDDYS LAB WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.